Table 4.

Tumor response and survival for cases and controls during ICI therapy.

	Case, n (%)	Control, n (%)	p-value
Tumor response on ICI by RECIST criteria			0.3362
Complete response	3 (27.3%)	4 (18.2%)
Partial response	2 (18.2%)	9 (40.9%)
Stable disease	0 (0.0%)	2 (9.1%)
Progressive disease	6 (54.5%)	7 (31.8%)
Tumor response in subjects with grade 3+ IRAEs			0.4594
Complete response	2 (66.7%)	1 (25.0%)
Partial response	1 (33.3%)	2 (50.0%)
Stable disease	0 (0.0%)	1 (25.0%)
Progressive disease	0 (0.0%)	0 (0.0%)
Overall survival			0.7661
>3 years	4 (36.4%)	7 (31.8%)
1–3 years	2 (18.2%)	3 (13.6%)
<1 year	5 (45.5%)	10 (45.5%)
Unknown	0 (0.0%)	2 (9.1%)

IRAEs, immune-related adverse events; RECIST, Response evaluation criteria in solid tumors.